Potential clinical applications of siRNA technique: benefits and limitations

Eur J Clin Invest 2011; 41 (2): 221–232

[1]  M. Prato,et al.  Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. , 2009, Small.

[2]  L. Bonetta.  RNA-Based Therapeutics: Ready for Delivery? , 2009, Cell.

[3]  Xuchao Xue,et al.  A small interfering RNA targeting osteopontin as gastric cancer therapeutics. , 2008, Cancer letters.

[4]  Tao Chen,et al.  Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells. , 2008, International immunopharmacology.

[5]  A. Aigner,et al.  In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. , 2009, Toxicology and applied pharmacology.

[6]  M. Wirth,et al.  Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. , 2008, International journal of oncology.

[7]  V. Poli,et al.  IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing , 2009, Leukemia.

[8]  W. Shen,et al.  Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo , 2009, Journal of experimental & clinical cancer research : CR.

[9]  D. Mayer,et al.  Trastuzumab-induced cardiotoxicity. , 2009, Oncology nursing forum.

[10]  S. Awasthi,et al.  Regression of prostate cancer xenografts by RLIP76 depletion. , 2009, Biochemical pharmacology.

[11]  W. Seeger,et al.  Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model , 2009, Cancer Gene Therapy.

[12]  A. Noske,et al.  HMGA2 gene is a promising target for ovarian cancer silencing therapy , 2008, International journal of cancer.

[13]  M. Ogris,et al.  Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. , 2009, Molecular pharmaceutics.

[14]  Hua Yu,et al.  Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice , 2009, Glia.

[15]  X. Shi,et al.  Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo , 2009, Cancer Gene Therapy.

[16]  R. Figlin,et al.  STAT3: a target to enhance antitumor immune response. , 2011, Current topics in microbiology and immunology.

[17]  A. Santel,et al.  RNA interference for therapy in the vascular endothelium. , 2010, Microvascular research.

[18]  Rob Lambkin-Williams,et al.  A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus , 2010, Proceedings of the National Academy of Sciences.

[19]  Lin Chen,et al.  Lentivirus-mediated short hairpin RNA targeting the APRIL gene suppresses the growth of pancreatic cancer cells in vitro and in vivo. , 2008, Oncology reports.

[20]  J. S. Rao,et al.  Stat3-siRNA induces Fas-mediated apoptosis in vitro and in vivo in breast cancer. , 2009, International journal of oncology.

[21]  Rongxin Zhang,et al.  Adenovirus-mediated down-regulation of X-linked inhibitor of apoptosis protein inhibits colon cancer , 2009, Molecular Cancer Therapeutics.

[22]  W. Cai,et al.  Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. , 2007, Recent patents on anti-cancer drug discovery.

[23]  D Artemov,et al.  Imaging of cationic multifunctional liposome-mediated delivery of COX-2 siRNA , 2009, Cancer Gene Therapy.

[24]  Anil K Sood,et al.  Liposomal siRNA for ovarian cancer. , 2009, Methods in molecular biology.

[25]  P. Kaiser,et al.  RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. , 2010, American journal of ophthalmology.

[26]  V. Vetvicka,et al.  Depletion of procathepsin D gene expression by RNA interference – A potential therapeutic target for breast cancer , 2007, Cancer biology & therapy.

[27]  C. Gondi,et al.  RNAi‐mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease‐9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth , 2007, International journal of cancer.

[28]  W. Pardridge,et al.  Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. , 2009, Molecular pharmaceutics.

[29]  R. Sun,et al.  Antiapoptotic Activity of Autocrine Interleukin-22 and Therapeutic Effects of Interleukin-22-Small Interfering RNA on Human Lung Cancer Xenografts , 2008, Clinical Cancer Research.

[30]  V. Erdmann,et al.  Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy , 2008, Journal of Molecular Medicine.

[31]  A. Aigner.  Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo , 2007, Applied Microbiology and Biotechnology.

[32]  Xiao-wen He,et al.  Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. , 2008, Chinese medical journal.

[33]  Hiroki Uchida,et al.  A small interfering RNA targeting proteinase‐activated receptor‐2 is effective in suppression of tumor growth in a Panc1 xenograft model , 2008, International journal of cancer.

[34]  T. Park,et al.  Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[35]  X. Hao,et al.  Knockdown of survivin expression by siRNAs enhances chemosensitivity of prostate cancer cells and attenuates its tumorigenicity. , 2009, Acta biochimica et biophysica Sinica.

[36]  Motohiko Suzuki,et al.  A novel in vivo siRNA delivery system specifically targeting dendritic cells and silencing CD40 genes for immunomodulation. , 2009, Blood.

[37]  C. Gondi,et al.  RNA interference-mediated targeting of urokinase plasminogen activator receptor and matrix metalloproteinase-9 gene expression in the IOMM-lee malignant meningioma cell line inhibits tumor growth, tumor cell invasion and angiogenesis. , 2007, International journal of oncology.

[38]  T. Ochiya,et al.  RNAi-based drug discovery and its application to therapeutics. , 2008, IDrugs : the investigational drugs journal.

[39]  Weida Huang,et al.  RNA interference against hepatitis B virus with endoribonuclease-prepared siRNA despite of the target sequence variations. , 2007, Virus research.

[40]  L. Feldman,et al.  Local matrix metalloproteinase 2 gene knockdown in balloon‐injured rabbit carotid arteries using nonviral‐small interfering RNA transfection , 2009, The journal of gene medicine.

[41]  T. Kissel,et al.  In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure. , 2009, Bioconjugate chemistry.

[42]  C. Gondi,et al.  RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. , 2007, International journal of oncology.

[43]  S. Akhtar,et al.  Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity. , 2007, Advanced drug delivery reviews.

[44]  L. Feldman,et al.  Inhibition of MMP-2 gene expression with small interfering RNA in rabbit vascular smooth muscle cells. , 2007, American journal of physiology. Heart and circulatory physiology.

[45]  Tao Wang,et al.  Inhibition of non-small cell lung cancer cell proliferation and tumor growth by vector-based small interfering RNAs targeting HER2/neu. , 2009, Cancer letters.

[46]  D. Fan,et al.  Inhibition of osteopontin would suppress angiogenesis in gastric cancer. , 2007, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[47]  Svetlana Shulga Morskaya,et al.  RNA Interference-Mediated Silencing of the Respiratory Syncytial Virus Nucleocapsid Defines a Potent Antiviral Strategy , 2009, Antimicrobial Agents and Chemotherapy.

[48]  R. Hickerson,et al.  First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  M. Behlke.  Chemical modification of siRNAs for in vivo use. , 2008, Oligonucleotides.

[50]  Wen-juan Wang,et al.  Twist1-Mediated Adriamycin-Induced Epithelial-Mesenchymal Transition Relates to Multidrug Resistance and Invasive Potential in Breast Cancer Cells , 2009, Clinical Cancer Research.

[51]  A. Fowler,et al.  Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. , 2007, American journal of physiology. Heart and circulatory physiology.

[52]  M. Yano,et al.  Inhibition of hepatitis C virus infection and expression in vitro and in vivo by recombinant adenovirus expressing short hairpin RNA , 2007, Journal of gastroenterology and hepatology.

[53]  M. Duffy,et al.  Survivin: a new target for anti-cancer therapy. , 2009, Cancer treatment reviews.

[54]  F. Fan,et al.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver , 2008, Oncogene.

[55]  A. Hajri,et al.  Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. , 2009, Neoplasia.